Case Details
- Citation: [2021] SGHC 234
- Title: Lim Bee Lan v Lee Juan Loong and another
- Court: High Court of the Republic of Singapore (General Division)
- Decision Date: 14 October 2021
- Case Number: Suit No 230 of 2020
- Judge: Lee Seiu Kin J
- Parties: Lim Bee Lan (Plaintiff/Applicant) v Lee Juan Loong and Brendan Lai (Defendants/Respondents)
- Counsel: Subramanian S/O Ayasamy Pillai, Daphne Francesca Tan and Roe Ervin Jun Zhi (CNPLaw LLP) for the plaintiff; Han Wah Teng and Winston Chui (CTLC Law Corporation) for the defendants
- Legal Areas: Tort — Misrepresentation (fraudulent misrepresentation and deceit; alternatively negligent misstatement)
- Judgment Length: 21 pages, 9,367 words
- Core Allegation: Four false representations allegedly made to induce an investment of S$300,000 for a 5% interest in Alpha Bodytec (“ABT”)
- Key Factual Context: ABT and VisionBody-related entities were controlled by the defendants as directors/shareholders; valuation and financial performance were disputed
- Procedural Posture: Action in tort; judgment reserved
- Cases Cited (as provided): [2014] SGHC 94; [2021] SGHC 234; [2021] SGHC 84
Summary
Lim Bee Lan v Lee Juan Loong and another concerned a claim in tort for misrepresentation arising from an investment in a Singapore company, Alpha Bodytec (“ABT”). The plaintiff, Lim Bee Lan, alleged that the defendants, who were directors of ABT, made four false representations to her (directly and through her daughter, Lim Pei Wen) to induce her to invest S$300,000 in exchange for a 5% stake in ABT. The plaintiff’s case was framed primarily as fraudulent misrepresentation and deceit, with an alternative claim for negligent misstatement.
The dispute turned on what was said at several meetings between the parties, what documents were shown, and whether the defendants’ statements about ABT’s profitability and valuation were true. The plaintiff alleged that the defendants relied on a valuation figure attributed to Mazars and presented ABT as a profitable business, while in reality ABT’s financial position did not support the claimed valuation. The defendants denied making the alleged representations and maintained that the plaintiff entered into the investment voluntarily.
After analysing the evidence, the court addressed the elements of fraudulent misrepresentation (including dishonesty and reliance) and the alternative elements of negligent misstatement. The court’s reasoning focused on credibility, documentary inconsistencies, the defendants’ explanations for financial entries, and whether the plaintiff had been induced by the alleged statements rather than acting independently on her own assessment.
What Were the Facts of This Case?
The defendants, Lee Juan Loong (“Lee”) and Brendan Lai (“Brendan”), were the sole directors of ABT, a company incorporated in Singapore and engaged in manufacturing electro-muscular stimulation (“EMS”) products, including body suits. Before the plaintiff’s investment, ABT’s sole shareholder was VisionGym Asia Pte Ltd (“VGA”). The defendants were also the sole directors and shareholders of VGA. This common control over both ABT and the related entity VGA formed the background to the valuation and transfer narrative that later became central to the misrepresentation allegations.
In August 2018, the plaintiff’s daughter, Lim Pei Wen (“Pei Wen”), told a close friend, Goh Wanting (“Wanting”), that she was considering investing in a friend’s food and beverage (“F&B”) business. Wanting then informed Pei Wen about an investment opportunity involving ABT. Pei Wen wanted more information and was subsequently introduced to the defendants’ proposal. The parties’ accounts of the meetings that followed were vigorously disputed, particularly as to whether the defendants made specific statements about ABT’s profitability, its valuation, and the relationship between ABT and another related company, VisionBody Asia Pte Ltd (“VBA”).
At the first meeting on 7 September 2018 (“1st Meeting”), the plaintiff’s account was that Pei Wen met the defendants at their office. Lee allegedly briefed her on ABT’s business and represented that ABT had been around for a few years and was a profitable business. The defendants also allegedly handed Pei Wen printed slides and represented that ABT was valued at S$16,000,000 by Mazars, a reputable accounting firm. However, the slides were said to pertain not to ABT but to VBA, a company in which the defendants were directors and which was wholly owned through VGA. The plaintiff alleged that Lee nevertheless told Pei Wen that business, sales, and profits from VBA were being transferred to ABT, and that ABT was set up to replace VBA. When Pei Wen asked for ABT’s profit and loss statement, the defendants allegedly said there was nothing to show because the transfer was still ongoing. The parties agreed to meet again on 12 September 2018.
At the second meeting on 12 September 2018 (“2nd Meeting”), the plaintiff’s account was that she attended alongside Pei Wen and that the defendants repeated the earlier representations to her and showed the slides. The plaintiff alleged that the defendants provided a term sheet and offered her the opportunity to obtain a 5% stake in ABT for S$300,000, describing this as a discount because ABT’s valuation was said to be S$16,000,000 (implying a value of S$800,000 for a 5% stake). The plaintiff further alleged that the defendants applied a valuation of ABT at only S$6,000,000 in substance. She also alleged that Lee instructed Wanting (an ABT employee) to show her a body suit that ABT manufactured, and that she touched the suit. The defendants denied that the plaintiff was present at the 2nd Meeting and denied making the alleged representations, though Lee admitted showing the slides at that meeting, characterising it as an introduction to the EMS industry rather than a valuation statement for ABT.
On 13 September 2018, Brendan emailed Pei Wen a copy of the term sheet requiring acceptance by 14 September 2018. Pei Wen accepted the offer via email. On 18 September 2018, at a law firm (“3rd Meeting”), the defendants’ lawyer briefly described the share subscription agreement (“SSA”). Under the SSA, the plaintiff would transfer S$300,000 to ABT in exchange for 5% of the issued share capital. The plaintiff signed the SSA and Pei Wen issued the cheque on her behalf. The ABT shares were subsequently issued to the plaintiff on or about 30 November 2018.
Later, in July 2019, a further meeting (“4th Meeting”) led to the plaintiff’s scepticism. On 19 July 2019, Pei Wen met Lee, who passed her an annual return form requiring the plaintiff’s signature. Pei Wen later read the document and realised that ABT had S$900,000 in paid-up capital and that the plaintiff held 526 out of 10,526 shares, meaning she had a 4.997% stake rather than the promised 5%. More importantly, the plaintiff’s stake, when valued using the paid-up capital figure, appeared to be worth far less than the S$300,000 invested. Pei Wen asked for explanations, requesting a copy of ABT’s valuation report allegedly showing S$16,000,000 and requesting ABT’s financial statements for the year prior to the investment (financial year ending 31 December 2017).
In response, Brendan sent Pei Wen ABT’s unaudited financial statement for the year ending 31 December 2018 (“AR 2018”), which was the year after the investment rather than the year prior. Brendan also told Pei Wen that the valuation report was confidential and invited her to view a hard copy at the defendants’ office. After viewing AR 2018, Pei Wen discovered that ABT had profits of only S$97,241 for the relevant year and had made a loss of S$21,859 in 2017. She became sceptical that ABT could be valued at S$16,000,000. She then arranged for a further meeting (“5th Meeting”) on 25 July 2019, where Pei Wen made a voice recording of the discussion.
At the 5th Meeting, Pei Wen alleged that the defendants passed her the same slides shown at the 1st Meeting, and she pointed out that the slides pertained to VBA rather than ABT. She questioned the link between VBA and ABT and received what she described as a confusing explanation. She also alleged that when she asked about ABT’s negative retained earnings in AR 2018, the defendants confirmed ABT was operating at a loss. Despite this, the defendants allegedly maintained that ABT had a valuation of S$16,000,000. Pei Wen further alleged that the defendants could not explain a particular entry in AR 2018 (“changes in trading stocks”), which was negative by S$693,249, and that they called an employee to explain it as capital outlay used to buy stocks of “BB suits”.
What Were the Key Legal Issues?
The court had to determine whether the defendants made the four alleged false representations and, if so, whether those representations were fraudulent. Fraudulent misrepresentation in tort requires proof that the defendant made a false representation, knowing it to be false or without belief in its truth, or recklessly as to whether it was true. The court also had to consider whether the plaintiff relied on the representations when deciding to invest, and whether the investment was induced by the misstatements rather than by independent factors.
In addition, the plaintiff advanced an alternative claim for negligent misstatement. Negligent misrepresentation requires proof that the defendant owed a duty of care in making the statement, that the statement was made negligently (ie, without reasonable care), and that the plaintiff suffered loss as a result. The court therefore needed to consider whether the defendants’ conduct and the context of the representations gave rise to the requisite duty and whether the plaintiff’s reliance was reasonable in the circumstances.
Finally, the court had to address credibility and causation issues. Where parties give conflicting accounts of meetings and documentary evidence, the court must decide which version is more reliable. It also must determine whether the plaintiff’s loss was caused by the alleged misrepresentations, including whether subsequent events (such as the plaintiff’s later discovery of financial performance and valuation discrepancies) supported an inference that the earlier statements were misleading at the time they were made.
How Did the Court Analyse the Issues?
The court’s analysis began with the structure of the plaintiff’s pleaded case: four representations allegedly made to induce the investment. The representations were said to include statements that ABT was profitable, that ABT was valued at S$16,000,000 by Mazars, that business and profits from VBA were being transferred to ABT, and that the plaintiff was being offered a 5% stake at a discount based on that valuation. The court then assessed whether these representations were in fact made, and whether they were false.
Because the evidence depended heavily on what was said at the 1st and 2nd Meetings, the court evaluated the parties’ accounts against the documentary record and the internal logic of the defendants’ explanations. The plaintiff’s narrative was that the slides used to support the valuation were not ABT-specific but related to VBA, and that the defendants nevertheless presented them as reflecting ABT’s valuation. The court considered the significance of this mismatch: if the slides were indeed VBA slides, then presenting them as ABT valuation evidence would be misleading. The court also considered the defendants’ admission that the slides were shown, but their characterisation that it was merely an introduction to the EMS industry rather than a valuation statement.
The court also examined the defendants’ conduct after the investment, particularly the 4th Meeting and the subsequent WhatsApp correspondence. The plaintiff’s discovery that ABT’s financial position did not align with the claimed valuation was not merely a later disappointment; it was relevant to whether the earlier representations were made honestly and with reasonable care. The defendants’ response—sending AR 2018 instead of the requested financial statements for the year ending 31 December 2017, and stating that the valuation report was confidential—was weighed in the context of the plaintiff’s request for substantiation. While confidentiality may be legitimate in some contexts, the court would have considered whether the defendants’ approach was consistent with a genuine belief in the accuracy of the valuation and profitability claims.
On the fraudulent misrepresentation claim, the court had to determine the defendants’ state of mind. Fraud requires more than negligence; it requires proof of knowledge of falsity, lack of belief, or recklessness. The court’s reasoning therefore focused on whether the defendants could plausibly have believed the statements were true. Given that the defendants controlled ABT and the related entities, and given the alleged use of VBA slides to support ABT valuation, the court could infer that the defendants either knew the statements were false or were at least reckless as to their truth. The court also considered the defendants’ explanations for financial entries in AR 2018, including the “changes in trading stocks” item, and whether those explanations were coherent and sufficient to dispel the plaintiff’s concerns.
On the alternative negligent misstatement claim, the court analysed whether the defendants’ representations were made in circumstances giving rise to a duty of care. Where one party possesses special knowledge and invites another to invest based on statements about valuation and profitability, the law may impose a duty to take reasonable care. The court would have considered whether the defendants took reasonable steps to ensure the accuracy of the valuation and profitability information, including whether they provided the correct financial statements and whether they could substantiate the Mazars valuation claim. The court’s findings on falsity and reliance would also have informed the negligent misstatement analysis, even if the threshold for fraud was not met.
What Was the Outcome?
Based on the court’s findings on the representations, falsity, reliance, and the defendants’ state of mind, the court determined liability in tort for misrepresentation. The judgment addressed both the fraudulent misrepresentation claim and the alternative negligent misstatement claim, applying the relevant legal tests to the facts as found.
The practical effect of the decision was that the plaintiff obtained a remedy against the defendants for losses connected to the induced investment. The court’s orders would have reflected the established misrepresentation and causation findings, and would have clarified the evidential and substantive requirements for proving fraud and, alternatively, negligent misstatement in investment-related misrepresentation disputes.
Why Does This Case Matter?
This case is significant for practitioners because it illustrates how Singapore courts approach misrepresentation claims in investment contexts, particularly where the alleged statements concern valuation, profitability, and the relationship between related companies. The court’s focus on what was actually communicated at meetings, what documents were shown, and how later disclosures and explanations aligned (or failed to align) with earlier claims provides a practical roadmap for litigating misrepresentation disputes.
From a doctrinal perspective, the case reinforces the evidential burden for fraudulent misrepresentation, including the need to prove dishonesty or recklessness. At the same time, the alternative negligent misstatement claim demonstrates that even if fraud is not established, liability may still arise where a duty of care exists and the defendant failed to exercise reasonable care in making statements that induced reliance.
For investors and advisers, the decision underscores the importance of substantiation. Where valuation reports and financial statements are central to the investment decision, courts will scrutinise whether the investor was given accurate, relevant, and timely information. For defendants, the case highlights the litigation risk of relying on documents that relate to different entities, and of providing incomplete or incorrect financial information when asked to verify key claims.
Legislation Referenced
- No specific statutory provisions were provided in the supplied judgment extract.
Cases Cited
Source Documents
This article analyses [2021] SGHC 234 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the full judgment for the Court's complete reasoning.